This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adamson, A. L.
Right arrow Articles by Kenney, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adamson, A. L.
Right arrow Articles by Kenney, S.

 Previous Article  |  Next Article 

Journal of Virology, February 2000, p. 1224-1233, Vol. 74, No. 3
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Epstein-Barr Virus Immediate-Early Proteins BZLF1 and BRLF1 Activate the ATF2 Transcription Factor by Increasing the Levels of Phosphorylated p38 and c-Jun N-Terminal Kinases

Amy L. Adamson,1 Dayle Darr,1 Elizabeth Holley-Guthrie,1 Robert A. Johnson,1,2 Amy Mauser,1 Jennifer Swenson,1 and Shannon Kenney1,2,3,*

Lineberger Comprehensive Cancer Center,1 Department of Medicine,2 and Department of Microbiology and Immunology,3 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7295

Received 8 June 1999/Accepted 1 November 1999


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Expression of either Epstein-Barr virus (EBV) immediate-early protein BZLF1 (Z) or BRLF1 (R) is sufficient to convert EBV infection from the latent to lytic form. Disruption of viral latency requires transcriptional activation of the Z and R promoters. The Z and R proteins are transcriptional activators, and each immediate-early protein activates expression of the other immediate-early protein. Z activates the R promoter through a direct binding mechanism. However, R does not bind directly to the Z promoter. In this study, we demonstrate that the ZII element (a cyclic AMP response element site) in the Z promoter is required for efficient activation by R. The ZII element has been shown to be important for induction of lytic EBV infection by tetradecanoyl phorbol acetate and surface immunoglobulin cross-linking and is activated by Z through an indirect mechanism. We demonstrate that both R and Z activate the cellular stress mitogen-activated protein (MAP) kinases, p38 and JNK, resulting in phosphorylation (and activation) of the cellular transcription factor ATF2. Furthermore, we show that the ability of R to induce lytic EBV infection in latently infected cells is significantly reduced by inhibition of either the p38 kinase or JNK pathways. In contrast, inhibition of stress MAP kinase pathways does not impair the ability of Z expression vectors to disrupt viral latency, presumably because expression of Z under the control of a strong heterologous promoter bypasses the need to activate Z transcription. Thus, both R and Z can activate the Z promoter indirectly by inducing ATF2 phosphorylation, and this activity appears to be important for R-induced disruption of viral latency.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Epstein-Barr virus (EBV) is a member of the human herpesvirus family of viruses and is the causative agent of infectious mononucleosis (61). EBV has also been found in association with a variety of cancers, including Burkitt's lymphoma and nasopharyngeal carcinoma (61, 82). Upon primary infection, EBV infects epithelial cells, where it undergoes lytic replication, and B cells, where it usually remains latent (37, 45, 61, 67). However, in a small percentage of B cells, latent EBV can become reactivated and undergo lytic replication. This viral reactivation is initiated by the two EBV immediate-early proteins, BZLF1 and BRLF1 (5, 8, 36, 57, 62, 63, 69, 77, 80).

The BZLF1 (Z) and BRLF1 (R) proteins function as transcriptional activators of the EBV early genes (9, 20, 28-30, 35, 46, 56, 74), and the expression of either Z or R is sufficient to induce lytic replication in both latently infected epithelial cells and B cells (5, 8, 57, 69, 77, 80). Regardless of which immediate-early gene is initially transcribed, expression of one immediate-early protein leads to the expression of the other (80), and full activation of early genes requires the presence of both immediate-early proteins (1, 80). Z activates the R promoter by directly binding to Z-response elements (ZREs) (1, 66). However, the mechanism by which R activates Z expression remains unknown. Although the R protein binds directly to a GC-rich motif present in enhancer elements upstream of several EBV early promoters (24, 25, 56), there are no known R binding sites within the Z promoter (25). Thus, R could potentially activate the Z promoter through an indirect mechanism involving modulation of a cellular transcription factor.

The ZII element in the Z promoter functions as an important positive regulator of Z transcription (16). ZII is required for both efficient tetradecanoyl phorbol acetate induction of Z transcription (16) and activation induced by surface immunoglobulin (Ig) cross-linking (10). In addition, human herpesvirus 6 (HHV-6) infection has been shown to activate the Z promoter through this site (14). Mutant forms of Z unable to bind DNA have also been shown to activate transcription dependent upon the ZII element (15), although the exact mechanism for this effect remains unknown. Previous reports, as well as data from our own laboratory, have shown that the cellular factors binding to the ZII element include CREB, ATF1, ATF2, and c-Jun (49, 76). Of these proteins, CREB and ATF1 have been reported to activate the Z promoter in reporter gene assays (49, 76).

CREB, ATF1, and ATF2 are all members of the CREB/ATF family of transcription factors that bind directly to DNA via cyclic AMP-response elements (CREs), and each of these proteins requires phosphorylation in order to function efficiently as transcriptional activators (22, 26, 51, 58, 60, 75). Activation of the CREB and ATF1 proteins occurs primarily through phosphorylation by protein kinase A (PKA) (22, 60), whereas ATF2 is activated after phosphorylation by either the p38 or c-Jun-N-terminal (JNK) stress kinases (26, 58, 75). JNK-mediated phosphorylation is also required for activation of the c-Jun transcription factor (11, 42), which can heterodimerize with ATF2 (27). Thus, activation of Z transcription through the ZII element could potentially be mediated through phosphorylation of the CRE family and/or c-Jun transcription factors.

Here we have studied the effects of R and Z expression upon the cellular transcription factors binding to the ZII motif. We demonstrate that although neither R nor Z expression significantly affects the levels of CREB, ATF1, ATF2, or c-Jun binding to ZII, R and Z both induce phosphorylation of p38 kinase as well as JNK. Furthermore, we find that the ability of R to disrupt viral latency efficiently requires activation of the stress mitogen-activated protein (MAP) kinase cascade. These results suggest that a key initial step in the disruption of viral latency by R is the activation of JNK and p38 kinase, thereby allowing R to induce Z transcription through phosphorylation of the ATF2 and c-Jun transcription factors.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Cell lines. DG75 is an EBV-negative Burkitt's lymphoma cell line. Akata (68) and Raji are EBV-positive Burkitt's lymphoma cell lines. B95-8 is an EBV-positive marmoset B-cell line. HeLa is a cervical carcinoma cell line. NIH 3T3 is a mouse fibroblast cell line. NPC-KT is an EBV-positive epithelial cell line derived from the fusion of a human adenoidal epithelial cell line and a primary EBV-positive nasopharyngeal carcinoma (70). D98/HE-R-1 is an epithelial cell line formed by fusion of a HeLa cell subclone (D98) with the EBV-positive Burkitt's lymphoma cell line P3HR/1 (21). All lymphoid cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum. Epithelial cell lines were maintained in Dulbecco's modified Eagle's medium H supplemented with 10% fetal calf serum.

Adenovirus construction and infection. The BZLF1 and BRLF1 cDNAs were cloned into a shuttle vector (under the control of the cytomegalovirus [CMV] promoter) which contains a Lox P site, the left adenovirus terminal repeat, and a packaging signal. These vectors were recombined (in a cell line expressing the phage P1 Cre protein) into the Lox P site of an adenovirus lacking the E1 and E3 genes, to create adenovirus-Z and adenovirus-R, as previously described (77). A control vector (adenovirus-LacZ) containing the lacZ gene was made in the same manner.

HeLa cells were plated at a cell density of 3 × 106 cells per 140 by 20 mm plate. Cells were infected with no adenovirus (mock), adenovirus-LacZ, adenovirus-Z, or adenovirus-R at a multiplicity of infection of 50. The cells were harvested 24 to 48 h postinfection.

Plasmids. EApBS-CAT contains the early EBV BMRF1 promoter sequences from -331 to +1 linked to the chloramphenicol acetyltransferase (CAT) gene (56). Gal4-E1b-CAT (gift of Michael Green) contains five copies of the Gal4 DNA binding site upstream of the E1B minimal TATA element and the CAT gene (47). ZpBS-CAT contains the immediate-early EBV BZLF1 promoter sequences from -552 to +12 linked to the CAT gene (1). -221 Zp-CAT contains the immediate-early EBV BZLF1 promoter sequences from -221 to +12 linked to the CAT gene, while -221 ZpZIIm-CAT contains a mutated ZII element (AAACGAATTCATCACAGAG) (16) (gifts of Erik Flemington).

The R expression vector (RTS15) contains the R genomic sequence under the control of the simian virus 40 early promoter (a gift from Diane Hayward). The wild-type Z expression vector contains the BZLF1 cDNA, downstream of the CMV immediate-early promoter, in the pHD1013 vector (56). The ZDelta LZ vector has a deletion of the Z leucine zipper from amino acid 196 to amino acid 228. The Z311 vector contains a mutation in the DNA binding domain of Z in which amino acid 185 is altered (abolishing DNA binding) (20, 34). Z-CT (previously referred to as RAZDelta R), has a deletion of Z amino acids 2 to 86 (a gift of Joseph Pagano) (18). The SG424 vector contains the GAL4 DNA binding domain alone (amino acids 1 to 147), whereas the Gal4-CREB, GAL4-ATF1, and GAL4-ATF2 constructs contain the indicated cDNAs linked in frame to GAL4 (gifts of Michael Green) (39, 64). GAL4-c-Jun contains the c-Jun cDNA fused to the Gal4 DNA binding domain in the SG424 vector (a gift of Al Baldwin). RSV (Rous sarcoma virus)-ATF2 contains the ATF2 cDNA in the RSV-pECE vector, and RSV-ATF1 contains the ATF1 cDNA in the RSV-pECE vector (gifts of Michael Green) (48). RSV-CREB contains the CREB cDNA (gift of Michael Green) (22). CMV-p38 contains the human p38 cDNA (a gift of Roger Davis) in the pcDNA3 vector. CMV-JNK contains the JNK cDNA in the pcDNA3B vector, and CMV-cdc42 contains the cdc42QL cDNA in the pcDNA3B vector (gifts from Lynn Vitale Cross). The PKA expression vector contains the catalytic subunit of PKA (mouse), under the mouse metallothionein 1 promoter (gift from Stanley McKnight) (73). Dominant-negative MKK3 contains a mutation at amino acid 193 of threonine to alanine, under the RSV promoter, in the pRc/RSV vector, and dominant-negative MKK6 contains a mutation at amino acid 82 of lysine to alanine, under the CMV promoter, in the pcDNA3 vector (59). GST (glutathione S-transferase)-c-Jun contains the first 79 amino acids of c-Jun linked to GST (a gift from Shelley Earp). The JIP-1 expression vector (12) is a gift from Roger Davis.

DNA purification. Plasmid DNA was purified through QIAGEN columns as described by the manufacturer.

DNA transfection. DNA (5 to 10 µg) was transfected into cells by electroporation with a Zapper electroporation unit (Medical Electronics Shop, University of Wisconsin) at 1,500 V as described previously (71). All cells were resuspended in RPMI 1640 medium prior to electroporation.

NIH 3T3 cells were transfected with Lipofectamine (Gibco BRL) as per the manufacturer's instructions.

CAT assays. Cell extracts were prepared 48 h posttransfection and incubated at 37°C with [14C]chloramphenicol in the presence of acetyl coenzyme A as described previously (23). The percent acetylation of chloramphenicol was quantitated by thin-layer chromatography followed by PhosphorImager screening (Molecular Dynamics).

Immunoblot analysis. Immunoblot analysis was performed for the detection of total ATF-2, CREB, p38, MKK3, MKK6, BMRF1, Z, and R proteins as follows. Briefly, 10 to 100 µg of protein was loaded in each lane, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed. The proteins were transferred overnight onto nitrocellulose (Protran), blocked in 1× phosphate-buffered saline (PBS)-5% milk-0.1% Tween 20, and incubated in primary antibody for 1 h at room temperature (ATF2 and CREB [1:500] from Santa Cruz, p38 [1:1,000] from New England Biolabs, MKK3 and MKK6 [1:1,000] from New England Biolabs, BMRF1 [1:100] from Capricorn, anti-EBV ZEBRA [1:100] from Argene or Z125 [1:50], from Alain Sergeant, and R [1:100] from Argene). The membrane was washed in PBS-0.1% Tween 20, incubated in secondary antibody for 1 h at room temperature {goat anti-mouse-kappa conjugated with horseradish peroxidase (GAM-kappa-HRP [1:2,000]) from Southern Biotechnology, goat anti-rabbit-HRP [1:10,000] from Promega} and washed, and the results were visualized with the ECL enhanced chemiluminescence kit (Amersham) according to the manufacturer's instructions.

The detection of phosphorylated ATF2, CREB/ATF1, p38, MKK3, and MKK6 proteins differed as follows: membranes were blocked in 1× Tris-buffered saline (TBS)-0.1% Tween 20-5% milk and washed with TBST (1× TBS-0.1% Tween 20). The primary antibody was diluted in 1× TBS-0.1% Tween 20-5% bovine serum albumin (BSA) and was incubated overnight at 4°C (phospho-ATF2, phospho-CREB/ATF1, phospho-MKK3, phospho-MKK6, and phospho-p38 [1:1,000] from New England Biolabs). The secondary antibody was diluted in blocking solution and was incubated for 1 h at room temperature.

Protein preparation. B95-8 cells were washed twice with PBS, resuspended in 200 µl of extraction buffer (50 mM HEPES [pH 7], 250 mM NaCl, 0.1% NP-40, 5 mM EDTA, 5 mM dithiothreitol [DTT], protease inhibitors), freeze-thawed twice, and centrifuged. The supernatant was used for electrophoretic mobility shift assays (EMSAs).

Adenovirus-infected HeLa cells were resuspended in low-salt buffer (150 mM NaCl, 20 mM Tris [pH 7.5], 5 mM EDTA, 1% Triton X-100, 50 mM NaF, 10% glycerol, 1 mM NaVO4, protease inhibitors). Cell lysates were tumbled for 15 min at 4°C and centrifuged. The supernatant was used for Western blots.

Transfected or adenovirus-infected NPC-KT cells or D98/HE-R-1 cells were resuspended in 50 µl of buffer (0.25 M NaCl, 0.1% NP-40, 0.05 M HEPES [pH 7], 5 mM EDTA, protease inhibitors), freeze-thawed twice, and centrifuged. The supernatant was used for Western blots.

Cells treated with the p38 kinase inhibitor SB 202190 (Calbiochem) were incubated in medium containing a final concentration of 10 µM inhibitor for 24 h.

GST-c-Jun was induced, and cells were sonicated and centrifuged. The supernatant was incubated with glutathione-agarose beads for 30 min at room temperature, and the beads were washed three times with PBS.

Kinase assays. HeLa cells were infected with adenovirus-LacZ, adenovirus-Z, or adenovirus-R for 24 h, washed twice with PBS, and lysed in 0.9 ml of low-salt buffer (150 mM NaCl, 20 mM Tris [pH 7.5], 5 mM EDTA, 1% Triton X-100, 50 mM NaF, 10% glycerol, 1 mM NaVO4, protease inhibitors). Cell lysates were tumbled for 15 min at 4°C and centrifuged. One hundred fifty micrograms of protein was incubated with GST-c-Jun-beads, tumbled for 2 h at 4°C, and centrifuged. The beads were washed three times with low-salt buffer and then washed one time with kinase buffer (7× buffer = 140 mM HEPES [pH 7.5], 70 mM MgCl2, 350 mM NaCl, 7 mM DTT, 35 mM B-glycerophosphate, 10.5 mM EGTA). The beads were incubated in 35 µl of reaction mix (per reaction, 5 µl of 7× kinase buffer, 10 mM ATP, 1 µl of [gamma -32P]ATP, distilled water to 35 µl) for 10 min at 30°C and centrifuged, and the beads were loaded onto an SDS-PAGE (12% polyacrylamide) gel. After electrophoresis, the gel was dried and exposed to X-ray film.

EMSAs. EMSAs were performed as previously described (19). The synthetic double-stranded oligonucleotide used in the binding reactions was 5'-end labeled with 32P by using the Klenow reaction. The ZII double-stranded oligonucleotide consists of the single-stranded oligonucleotides 5' AGCTTCCATGACATCACAGAGGAGGCTGGGATC 3' and 5' GATCCCAGCCTCCTCTGTGATGTCATGGAAGCT 3'. The binding reactions were conducted in a buffer consisting of 60 mM potassium chloride, 12 mM HEPES (pH 7.9), 4 mM Tris-HCl (pH 7.9), 10% glycerol, 1 mM EDTA, and 1 mM DTT, with 4 µg of poly(dI-dC)-poly(dI-dC) (Pharmacia). Twenty micrograms of B95-8 cell extract was added, and the mixture was incubated at room temperature for 10 min prior to the addition of labeled probe (20,000 cpm). For supershifts, the protein extract was incubated with 3 µg of each antibody (ATF1, ATF2, CREB, or c-Jun from Santa Cruz) for 45 min prior to the binding reaction. The sequences of the competitors are as follows: SP1, 5'-ATTCGATCGGGGCGGGGCGAGC-3' and 3'-TAAGCTAGCCCCGCCCCGCTCG-5'; and CREB, 5'-AGAGATTGCCTGACGTCAGAGAGCTAG-3' and 3'-TCTCTAACGGACTGCAGTCTCTCGATC-5'. Each competitor was used at 200-fold excess over the probe. After addition of the probe, the reaction mixtures were incubated for 30 min at room temperature and then loaded onto a 4% polyacrylamide gel and run in 1× Tris-glycine-EDTA (TGE) at room temperature.

FACS analysis. Anti-IgG-treated Akata cells (100 µg of antihuman IgG per ml [Sigma] for 4 h), in the absence or presence of 10 µM p38 inhibitor SB 202190 (Calbiochem), were washed twice with PBS, fixed with 60% acetone for 10 min on ice, washed three times with PBS-0.5% BSA and incubated with a 1:100 dilution of the primary antibody (BMRF1 [Capricorn], Z [Argene], or R [Argene]) for 1 h at room temperature. The cells were washed three times and then incubated in the secondary antibody (GAM fluorescein isothiocyanate [1:100], from Sigma) for 1 h at room temperature. The cells were washed three times and resuspended in 0.5 ml of PBS. The percentage of immunofluorescent cells was determined with a FACS machine (Becton Dickinson).


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The ZII element is an important component for R-mediated activation of the Z promoter. Although the R protein has been previously shown to activate the Z promoter (80), there are no known R-binding sites in the Z promoter. The Z promoter contains an upstream regulatory element, referred to as ZII, that has been previously shown to be an important positive regulator of Z transcription (10, 14, 16, 65). To examine whether the ZII element plays a role in R activation of Z expression, we examined the effect of R on Z promoter activity by using Z promoter constructs that contain either a wild-type (-221 Zp-CAT) or mutant (-221 ZpZIIm-CAT) ZII element, in DG75 (EBV-negative) and Raji (EBV-positive) cell lines (Fig. 1). In both cell lines, R activation of the wild-type promoter was significantly higher than activation of the promoter containing a mutant ZII site. Therefore the ZII element plays a major role in R activation of the Z promoter.


View larger version (11K):
[in this window]
[in a new window]
  		FIG. 1.   R activates the Z promoter through the ZII element. DG75 or Raji cells were transfected with 5 µg of promoter construct (-221 Zp-CAT or -221 ZpZIIm-CAT) and 1 µg of vector control DNA or R expression plasmid. CAT assays were performed. The fold activation, relative to vector alone, is shown. Error bars indicate range.

The ZII element of the Z promoter binds ATF1, ATF2, CREB, and c-Jun. ZII was originally identified as an AP1 site (16), but has since been shown to be a CRE site (4, 49, 76). We performed EMSAs with an oligonucleotide probe spanning the ZII element and B95-8 cell extracts. As shown in Fig. 2 (left panel), a CRE competitor oligonucleotide competed the top two binding complexes (labeled A and B), while a control competitor oligonucleotide (Sp1) did not. An anti-ATF1 antibody supershifted protein, although it is difficult to determine which complex is being supershifted. Anti-ATF2 and anti-c-Jun antibodies both supershifted proteins from the upper CRE complex (left panel), while an anti-CREB antibody blocked formation of the lower CRE complex (right panel). These results suggest that the A complex contains predominantly ATF2 and c-Jun, while the B complex contains predominantly CREB (and possibly ATF1). The finding that ATF1, ATF2, CREB, and c-Jun bind to the ZII element has recently been obtained by two other laboratories (14, 49, 76).


View larger version (47K):
[in this window]
[in a new window]
  		FIG. 2.   ATF1, ATF2, CREB, and c-Jun bind to the ZII element of the Z promoter. EMSAs were performed with a 32P-labeled ZII probe and B95-8 protein extracts. (Left panel) Twenty micrograms of protein extract was incubated in the absence (lane 2) or presence of a CRE consensus DNA competitor (lane 3) or an Sp1 consensus DNA competitor (lane 4); in the presence of antibodies directed against ATF1 (lane 5), ATF2 (lane 6), c-Jun (lane 7), or ATF2 plus c-Jun (lane 8); or a control antibody (lane 9). (Right panel) Twenty micrograms of protein extract was incubated in the absence (lane 1) or presence of antibodies directed against CREB (lane 2) or a control antibody (lane 3). A and B indicate the two pertinent complexes. The antibodies alone did not induce supershifts in the absence of cellular extract (data not shown).

CREB, ATF1, ATF2, and c-Jun activate the Z promoter. The ZII regulatory element is a positive regulator of the Z promoter, suggesting that factors which bind to ZII may activate the Z promoter. To examine whether CREB, ATF1, ATF2, or c-Jun is able to activate Zp, we cotransfected a Z promoter construct (linked to the CAT gene) with expression vectors for either CREB, ATF1, ATF2, or c-Jun, plus the kinases known to activate each of these transcription factors (Fig. 3A). CREB, ATF1, ATF2, and c-Jun each activate the intact Z promoter in the presence of the appropriate kinases. Similar results were previously obtained for the ATF1/CREB factors (14, 76); this is the first demonstration that phosphorylated ATF2 also activates the Z promoter. While the ATF2 and c-Jun transcription factors require the ZII motif for activation of the Z promoter, CREB and ATF1 both retained the ability to activate the mutant Z promoter construct. Therefore, CREB and ATF1 may also activate the Z promoter through motifs other than ZII. To confirm that efficient ATF2 and c-Jun activation of the Z promoter requires p38 kinase and/or JNK, we compared the effect of ATF2 and c-Jun with or without p38 kinase or JNK (Fig. 3C). As expected, maximal activation of the Z promoter required cotransfection with both a transactivator (ATF2 or c-Jun) and a kinase. JNK and p38 kinase alone, however, also induced some activation of the Z promoter, likely reflecting the ability of these kinases to activate endogenous ATF2 and c-Jun.


View larger version (13K):
[in this window]
[in a new window]
  		FIG. 3.   CREB, ATF1, ATF2, and c-Jun activate the Z promoter. (A) DG75 cells were transfected with 5 µg of ZpBS-CAT and 1 µg of transactivator plasmid (vector alone, CREB, ATF1, ATF2, or c-Jun), along with 1 µg of the appropriate kinase expression vectors to activate each transactivator (PKA for CREB and ATF1; p38, JNK, and cdc42 for ATF2; and JNK and cdc42 for c-Jun). (B) DG75 cells were transfected with 5 µg of -221 ZpZIIm-CAT and 1 µg of transactivator plasmid (vector alone, CREB, ATF1, ATF2, or c-Jun), along with 1 µg of the appropriate kinase expression vectors to activate each transactivator (PKA for CREB and ATF1; p38, JNK, and cdc42 for ATF2; and JNK and cdc42 for c-Jun). (C) DG75 cells were transfected with 5 µg of ZpBS-CAT, along with either 1 µg of transactivator plasmid (vector alone, ATF2 or c-Jun), 1 µg of kinase (p38 or JNK and cdc42), or a combination of these plasmids as indicated. CAT assays were performed as described. The average fold activation (and range), relative to vector alone, is presented.

Z and R increase the level of phosphorylated ATF2. Since CREB, ATF1, ATF2, and c-Jun activate the Z promoter, we examined whether the expression of Z or R affects Z transcription by altering the levels of protein binding to ZII. Electromobility gel shift assays were performed with a ZII probe and extracts of HeLa cells infected with adenovirus-LacZ, adenovirus-Z, or adenovirus-R (data not shown). The expression of either Z or R in the HeLa cells had a minimal effect upon the level of protein binding to ZII. Therefore, neither Z nor R activates the Z promoter by increasing the levels of cellular transactivators binding to the ZII element.

The CREB, ATF1, and ATF2 transcription factors require phosphorylation by PKA (CREB and ATF1), p38 (ATF2), or JNK (c-Jun and ATF2) for efficient transactivation function. Therefore, we examined whether Z or R increases the levels of phosphorylated ATF2, CREB, or ATF1. In extracts of HeLa cells that had been infected with adenovirus-LacZ, adenovirus-Z, or adenovirus-R (Fig. 4A), total ATF2 levels were unchanged after expression of either Z or R. In the same extracts, however, by using an antibody that specifically recognizes only the transcriptionally active (phosphorylated) form of ATF2, both Z and R were found to significantly increase the phosphorylation of ATF2. In contrast, R and Z did not consistently alter the levels of phosphorylated CREB or phosphorylated ATF1 (Fig. 4B).


View larger version (56K):
[in this window]
[in a new window]
  		FIG. 4.   Z and R increase phosphorylation of ATF2. HeLa cells were infected with adenovirus (Ad)-LacZ, adenovirus-Z, or adenovirus-R as indicated. Immunoblot analysis was performed with antibodies directed against total ATF2 and phosphorylated ATF2 (A) or total CREB and phosphorylated CREB/ATF1 (B). Both phosphorylated CREB and phosphorylated ATF1 are recognized by a single antibody. At least two separate experiments are presented for each antibody. Infection of cells with adenovirus-LacZ did not affect ATF2, ATF1, or CREB phosphorylation in comparison to levels in mock-infected cells (data not shown).

Z activates ATF2 and c-Jun transactivator functions in reporter gene assays. The finding that adenovirus-Z and adenovirus-R infections induce the activity of ATF2 by phosphorylation suggests that Z and R could indirectly activate the ZII site by inducing the transcriptional function of ATF2. We examined the ability of the CREB, ATF1, ATF2, and c-Jun proteins (fused to the yeast GAL4 DNA-binding domain) to activate a reporter construct containing five copies of the GAL4 DNA-binding site upstream of the adenovirus E1B TATA box, in the presence or absence of Z (Fig. 5A). Although Z clearly enhanced the transcriptional activator function of ATF2 and c-Jun, Z did not increase ATF1 transactivator function and decreased CREB transactivator function. Thus, Z primarily activates ATF2 and c-Jun (rather than ATF1 or CREB) transactivation function. These reporter gene assays also confirm that Z-mediated activation of ATF2 is not dependent upon any adenovirus-encoded proteins. We were unable to perform similar reporter gene assays with R, since R activated the GAL4-E1B-CAT reporter construct alone (in the absence of transactivators) to a high level (data not shown).


View larger version (18K):
[in this window]
[in a new window]
  		FIG. 5.   Z activates ATF2 and c-Jun transactivator functions. (A) DG75 cells were transfected with 5 µg of GAL4-E1B-CAT reporter construct and 1 µg of SG424 (GAL4 DNA-binding domain alone), GAL4-ATF1, GAL4-ATF2, GAL4-CREB, or GAL4-c-Jun, with or without the Z expression vector. CAT assays were performed as described in the text. The average fold activation (and range) relative to SG424 alone is presented. (B) Construction of Z deletion mutants. The location of the Z transactivator (TA) and DNA binding (DNA) and dimerization (DIM) domains is indicated. The Z311 construct is mutated at amino acid (a.a.) 185 (alanine to lysine) in the Z DNA binding domain and is defective in DNA binding. (C) DG75 cells were transfected with 5 µg of GAL4-E1B-CAT reporter construct, 1 µg of GAL4-ATF2, and 1 µg of either control vector, Z, Z311, Z-CT, or ZDelta LZ expression vectors. The ATF2 activation induced by each Z construct (relative to the activation induced by wild-type Z, set at 100%) is shown.

To examine the domains of Z required for activation of ATF2 transcriptional function, a series of Z mutants (Fig. 5B) were cotransfected with GAL4-ATF2 and the GAL4-E1B-CAT reporter. As shown in Fig. 5C, both the transactivation domain (Z-CT) and the leucine zipper dimerization domain (ZDelta LZ) of Z are required to activate ATF2. A mutation within the DNA binding domain of Z (Z311), which renders the protein unable to bind directly to Z-response elements or AP1 motifs, still activates ATF2 to some extent.

Z and R increase the activity of p38 and Jun kinases. Activation of ATF2 transcription function results from phosphorylation at Ser 69/71 by either p38 kinase or c-Jun-N-terminal kinase (JNK) (26, 58, 75). Since Z and R each increase the level of phosphorylated ATF2, we investigated whether Z and R increase the activities of p38 kinase and/or JNK. Extracts of HeLa cells that had been infected with adenovirus-LacZ, adenovirus-Z, or adenovirus-R were examined for activation of p38 kinase and JNK. p38 kinase activity was examined by immunoblot analysis with an antibody which specifically recognizes the active (phosphorylated) form of p38 kinase, or an antibody which recognizes both inactive and active (total) forms of p38 kinase (Fig. 6A). Although neither Z nor R expression increased the level of total p38 protein, Z and R both increased the level of phosphorylated p38. The level of active JNK was quantitated by comparing the phosphorylation of a GST versus a GST-c-Jun fusion protein (containing the amino-terminal region of c-Jun that is known to be phosphorylated by JNK), as described in Materials and Methods (Fig. 6B). R and Z both significantly increased JNK activity. Taken together, these results indicate that both R and Z activate ATF2 transactivator function by increasing the levels of active forms of p38 kinase and JNK.


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 6.   Z and R increase the levels of activated p38 kinase and JNK. (A) HeLa cells were infected with adenovirus (Ad)-LacZ, adenovirus-Z, or adenovirus-R as indicated. Immunoblot analysis was performed with antibodies directed against either total p38 or phosphorylated p38. The results from two separate experiments are presented. (B) Kinase assays were performed as described in the text with extracts from mock-, adenovirus-LacZ-, adenovirus-Z-, or adenovirus-R-infected HeLa cells. The negative and positive controls are extracts from HEL cells that were either UV irradiated (positive) or unirradiated (negative). Similar results were obtained in a second experiment (data not shown). Infection of cells with adenovirus-LacZ did not affect p38 kinase or JNK phosphorylation in comparison to levels in mock-infected cells (data not shown).

We considered the possibility that Z and R activation of the stress MAP kinases could be due to an irrelevant stress response induced by nonphysiologic overexpression of these proteins. However, by using immunofluorescence (FACS analysis) to quantitate the level of Z and R expression in the adenovirus-infected HeLa cells versus that in TPA-induced B95-8 cells, we found similar levels of cellular Z and R expression (data not shown). Thus, the levels of Z and R produced in HeLa cells infected by the Z and R adenoviruses are comparable to physiological levels of Z and R produced by the endogenous EBV genome.

The disruption of EBV viral latency by R is prevented by inhibitors of p38 kinase or JNK. JNK is activated by phosphorylation via SKK1/SKK4, while p38 kinase is activated (phosphorylated) by either SKK1/SKK4 or MKK3/MKK6 (11, 43, 64a). To determine which signal transduction pathway (p38 versus JNK) is important for the Z and R effects and whether activation of the stress MAP kinases is required for disruption of viral latency, we examined the ability of the R and Z adenovirus vectors to induce expression of an early lytic EBV gene, BMRF1, in NPC-KT (EBV-positive) cells in the absence or presence of the p38 inhibitor SB 202190 or JIP-1 (which inhibits JNK activity) (12). The specificities of these inhibitors are shown in Fig. 7A. SB 202190, which predominantly inhibits p38 kinase activity, significantly reduced the level of BMRF1 produced by adenovirus-R infection, while not affecting the level of BMRF1 produced by adenovirus-Z infection (Fig. 7B). The level of Z produced by adenovirus-R infection was also reduced by the p38 inhibitor, although the level of R in the adenovirus-R-infected cells was not affected. These data suggest that p38 kinase activation is important for the disruption of viral latency by R and, more specifically, for the ability of R to induce Z expression. Similarly, overexpression of the scaffolding JIP-1 protein (which inhibits JNK activity) also prevented the disruption of latency by R, but did not affect the ability of Z to disrupt latency (Fig. 7C).


View larger version (20K):
[in this window]
[in a new window]
  		FIG. 7.   p38 kinase and JNK are necessary for R to disrupt EBV viral latency. (A) DG75 cells were transfected with 5 µg of GAL4-E1B-CAT reporter construct, and 1 µg of SG424 or GAL4-ATF2, along with 1 µg of p38 or JNK expression plasmids, with or without the p38 inhibitor SB 202190 (10 µM) or 2 µg of JIP-1 expression plasmid. CAT assays were performed as described in the text. The ATF2 activation induced (relative to the activation induced by JNK alone or p38 kinase alone, set at 100%) is shown. (B) NPC-KT cells were infected with adenovirus-R or adenovirus-Z in the absence or presence of the p38 kinase inhibitor SB 202190 (10 µM). Immunoblot analysis was performed with antibodies directed against BMRF1, Z or R. Longer exposures indicated that the p38 inhibitor did not affect the level of R protein induced by adenovirus-Z. (C) D98/HE-R-1 cells were transfected with vector alone, R, Z, R plus JIP-1, or Z plus JIP-1 as indicated. Immunoblot analysis was performed with antibodies directed against BMRF1, R, or Z. (D) NIH 3T3 cells were transfected with p38 kinase or a combination of p38 kinase and the dominant-negative MKK3 or MKK6 expression plasmids (dnMKK3 or dnMKK6). Immunoblot analysis was performed with antibodies directed against phosphorylated p38 or total p38. (E) D98/HE-R-1 cells were transfected with vector alone, R, Z, R plus dnMKK3/dnMKK6, or Z plus dnMKK3/dnMKK6 as indicated. Immunoblot analysis was performed with antibodies directed against BMRF1.

To examine the effects of inhibition of upstream activators of p38 kinase, we transfected D98/HE-R-1 (EBV-positive) cells with expression plasmids for Z or R, with or without expression plasmids for dominant-negative forms of MKK3 and MKK6. As expected, both the MKK3 and MKK6 dominant-negatives inhibited phosphorylation of p38 (Fig. 7D). However, inhibition of MKK3 and MKK6 activities had little effect upon induction of BMRF1 expression by Z or R (Fig. 7E). Therefore, R activation of p38 kinase is unlikely to be mediated through MKK3 or MKK6. Taken together, these results suggest that activation of both JNK and p38 kinase is required for R-induced disruption of viral latency.

p38 kinase activation is also necessary for efficient disruption of viral latency by surface Ig cross-linking. To determine if p38 kinase is important for the disruption of latency induced by surface Ig cross-linking, we induced Akata cells with anti-IgG either in the absence or presence of the p38 kinase inhibitor SB 202190. We examined expression of BZLF1 and BMRF1 by immunofluorescence (FACS analysis) (Fig. 8). In the presence of the p38 kinase inhibitor, the number of cells expressing BZLF1 or BMRF1 after anti-IgG induction was significantly decreased. Therefore, p38 kinase activation is also necessary to efficiently disrupt EBV viral latency from the endogenous viral genome in B cells by surface Ig cross-linking.


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 8.   p38 kinase is important for the disruption of viral latency via anti-IgG cross-linking. Akata cells were treated with 100 µg of anti-IgG per ml for 24 h in the absence or presence of the p38 kinase inhibitor (inh.) SB 202190 (10 µM), and the percentage of cells positive for BZLF1 and BMRF1 expression was determined by BZLF1 and BMRF1 antibody staining and FACS analysis. Results are normalized such that the number of BZLF1- or BMRF1-positive cells for each experiment in the absence of drug is set at 100%. The average (and range) from two separate experiments is shown.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The EBV immediate-early proteins Z and R are important regulatory factors which together initiate lytic replication. Disruption of viral latency requires transcriptional activation of the Z and R promoters, and the ability of Z and R to activate one another's transcription appears to be a crucial aspect of this process (1, 80). Z activates the R promoter by a direct binding mechanism (1, 66). Our results here indicate that R activates Z transcription indirectly, by activating p38 kinase and JNK, thereby inducing phosphorylation of transcription factors (ATF2 and c-Jun) which bind to the ZII element of the Z promoter. Interestingly, members of the MEF2 transcription factor family, which bind to and activate the Z promoter through ZI motifs (3, 50), have also recently been shown to be phosphorylated (and at least in some cases activated) by p38 kinase (54, 78). Therefore, R-induced activation of p38 kinase and JNK could potentially induce BZLF1 transcription by a combined effect on several different transcription factors (ATF2, c-Jun, and MEF2) involving binding to both the ZI and ZII binding motifs. The finding that p38 kinase activation is required for efficient disruption of EBV latency by surface Ig cross-linking suggests that this pathway plays an important role in regulating the stringency of viral latency in vivo.

The ZII element is bound by CREB, ATF1, and an ATF2/c-Jun heterodimer. Potentially, phosphorylation of any one of these ZII-binding factors might be sufficient to activate the Z promoter, given our finding that each of these transcription factors activates the Z promoter in the presence of the appropriate activated kinase. Although it is possible that some stimuli (such as coinfection with HHV-6) induce lytic EBV infection through activation of CREB or ATF1, the effects of both R and Z on ZII-mediated transcription appear to be mediated through activation ATF-2 and c-Jun.

R and Z increase ATF2 phosphorylation through at least two different mechanisms. R and Z clearly increase the level of active (phosphorylated) p38 kinase, which is known to phosphorylate (and activate) ATF2. In addition, R and Z also induce JNK activity, which phosphorylates ATF2 at the same sites as p38 (26). Z activation of ATF2 requires the Z transactivation and leucine zipper domains of Z, but does not require Z DNA-binding activity. Therefore, Z likely modulates the p38 and JNK kinase pathways through protein-protein interactions. We have not yet defined the regions of R required for ATF2 phosphorylation.

Our finding that both of the EBV immediate-early proteins activate the stress MAP kinases suggests that activation of these kinases is important for efficient lytic EBV infection. Interestingly, another EBV protein, LMP-1, has also recently been shown to activate the JNK pathway (13, 38). The results from the p38 and JNK inhibitor studies suggest that R must activate both JNK and p38 kinase to disrupt viral latency in epithelial cells. The finding that efficient induction of lytic EBV infection through activation of the B-cell receptor (cross-linking of surface Ig) likewise requires p38 kinase activation suggests that this pathway is important for lytic EBV infection in B cells, as well.

However, even in the presence of the p38 kinase inhibitor, cross-linking of Ig produced some induction of lytic EBV infection (although greatly reduced). The residual induction of lytic EBV infection which occurs even in the absence of activated p38 kinase could be mediated through activated JNK. Alternatively, activation of the R promoter alone, since it directs transcription of a bicistronic R-Z message (53), is potentially sufficient to disrupt viral latency, albeit less efficiently.

Although both R and Z activate ATF-2 and c-Jun phosphorylation, only R has been shown to activate Z transcription from the endogenous EBV genome when transfected into latently infected cells (40, 44, 80). The inability of transfected Z to induce BZLF1 transcription from the endogenous viral genome may reflect the recent finding that Z interacts directly with CBP (CREB-binding protein) (2, 81). CREB transactivator function requires not only phosphorylation at amino acid 133, but also a direct interaction between CREB and CBP (6, 41). The amount of CBP in cells is limiting, and we have recently shown that Z inhibits CREB transcriptional function by competing for available CBP (2).

The ATF2 and c-Jun proteins also require direct interaction with CBP and/or p300 for optimal transactivator function (32, 33). Therefore, Z regulation of its own transcription likely reflects the balance between Z-induced stimulation (mediated through phosphorylation of ATF-2 and c-Jun, and possibly by direct Z binding to upstream ZRE sites [17]), versus Z-induced inhibition (mediated through competition for limiting amounts of cellular CBP). The overall effect of Z on its own transcription is likely dependent upon the availability of CBP and the amount of Z. We propose a model in which very low levels of Z protein initially activate BZLF1 transcription through phosphorylation of ATF-2 and/or c-Jun, but, as higher levels of Z protein accumulate, Z shuts down its own transcription through competition for limiting amounts of CBP and/or p300. In any event, the requirement for Z to stimulate its own transcription is clearly bypassed when Z is transfected into cells under the control of a strong heterologous promoter, and the predominant effect of such vectors instead may be competition for limiting amounts of CBP and/or p300 by Z.

A number of different types of cellular stresses (UV irradiation, osmotic shock, inflammatory cytokines, and growth factors, among others) induce activation of the cellular stress MAP kinases (7, 52, 72). Induction of the stress MAP kinase cascade has a multitude of phenotypic effects (including either induction of, or protection from, apoptosis), depending upon the cell type and circumstances. Activation of the stress MAP kinase cascade may be a common response of cells to infection by viruses, as well. Interestingly, in addition to our findings with EBV, CMV infection has been shown to activate p38 kinase (31), and HSV-1 infection has been shown to activate p38 kinase and JNK (55, 79), and activation of at least one of these kinases is likewise required for efficient lytic viral replication by both of these viruses. It is quite remarkable that three different herpesviruses (herpes simplex virus type 1, CMV, and EBV) take advantage of (and in fact, amplify) a normally protective response to cellular stress and use it to induce replication of their own genomes. Inhibition of p38 kinase and/or JNK activities may therefore prove to be an effective mechanism for preventing viral replication of a variety of herpesviruses.


    ACKNOWLEDGMENTS

This work was supported by grants RO1-CA58853, RO1-CA66519, and PO1-CA19014 from the National Institutes of Health. R.A.J. is a Virology Training grant recipient (2T32 AI07419).

We thank Roger Davis, Erik Flemington, and Diane Hayward for plasmids and the UNC Gene Therapy Core (R. Jude Samulski and Douglas McCarty) for preparing adenovirus-LacZ, adenovirus-Z, and adenovirus-R.


    FOOTNOTES

* Corresponding author. Mailing address: Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295. Phone: (919) 966-1248. Fax: (919) 966-8212. E-mail: shann{at}med.unc.edu.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Adamson, A. L., and S. C. Kenney. 1998. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product. Virology 251:187-197[CrossRef][Medline].
2. Adamson, A. L., and S. Kenney. 1999. The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase, CREB-binding protein. J. Virol. 73:6551-6558[Abstract/Free Full Text].
3. Borras, A. M., J. L. Strominger, and S. H. Speck. 1996. Characterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction. J. Virol. 70:3894-3901[Abstract].
4. Cen, H., and J. L. C. McKnight. 1994. EBV-immortalized isogenic human B-cell clones exhibit differences in DNA-protein complex formation on the BZLF1 and BRLF1 promoter regions among latent, lytic and TPA-activated cell lines. Virus Res. 31:89-107[CrossRef][Medline].
5. Chevallier-Greco, A., E. Manet, P. Chavrier, C. Mosnier, J. Daillie, and A. Sergeant. 1986. Both Epstein-Barr virus (EBV) encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an early EBV promoter. EMBO J. 5:3243-3249[Medline].
6. Chrivia, J. C., R. P. S. Kwok, N. Lamb, M. Hagiwara, M. R. Montminy, and R. H. Goodman. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855-859[CrossRef][Medline].
7. Cohen, P. 1997. The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol. 7:353-361.
8. Countryman, J., and G. Miller. 1985. Activation of expression of latent Epstein-Barr virus after gene transfer with a small cloned fragment of heterogeneous viral DNA. Proc. Natl. Acad. Sci. USA 82:4085-4089[Abstract/Free Full Text].
9. Cox, M. A., J. Leahy, and J. M. Hardwick. 1990. An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators. J. Virol. 64:313-321[Abstract/Free Full Text].
10. Daibata, M., S. H. Speck, C. Mulder, and T. Sairenji. 1994. Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B cells. Virology 198:446-454[CrossRef][Medline].
11. Derijard, B., M. Hibi, I. H. Wu, T. Barrett, B. Su, T. Deng, M. Karin, and R. J. Davis. 1994. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037[CrossRef][Medline].
12. Dickens, M., J. S. Rogers, J. Cavanagh, A. Raitano, Z. Xia, J. R. Halpern, M. E. Greenberg, C. L. Sawyers, and R. J. Davis. 1997. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693-696[Abstract/Free Full Text].
13. Eliopoulos, A. G., and L. S. Young. 1998. Activation of the c-Jun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731-1742[CrossRef][Medline].
14. Flamand, L., and J. Menezes. 1996. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus Zebra promoter by human herpesvirus 6. J. Virol. 70:1784-1791[Abstract].
15. Flemington, E. K., J. P. Lytle, C. Cayrol, A. M. Borras, and S. H. Speck. 1994. DNA-binding-defective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities. Mol. Cell. Biol. 14:3041-3052[Abstract/Free Full Text].
16. Flemington, E. K., and S. H. Speck. 1990. Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1217-1226[Abstract/Free Full Text].
17. Flemington, E. K., and S. H. Speck. 1990. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J. Virol. 64:1227-1232[Abstract/Free Full Text].
18. Furnari, F. B., V. Zacny, E. B. Quinlivan, S. Kenney, and J. S. Pagano. 1994. RAZ, an Epstein-Barr virus transdominant repressor that modulates the viral reactivation mechanism. J. Virol. 68:1827-1836[Abstract/Free Full Text].
19. Garner, M., and A. Rezvin. 1981. A gel electrophoresis method for quantifying the binding of proteins to specific DNA regions: application to components of the Escherichia coli lactose operon regulatory system. Nucleic Acids Res. 9:3047-3060[Abstract/Free Full Text].
20. Giot, J.-F., I. Mikaelian, M. Buisson, E. Manet, I. Joab, J.-C. Nicolas, and A. Sergeant. 1991. Transcriptional synergy and interference between the EBV transcription factors EB1 and R require both the basic region and the activation domains of EB1. Nucleic Acids Res. 19:1251-1258[Abstract/Free Full Text].
21. Glaser, R., and F. J. O'Neill. 1972. Hybridization of Burkitt lymphoblastoid cells. Science 176:1245-1247[Abstract/Free Full Text].
22. Gonzalez, G. A., and M. R. Montminy. 1989. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59:675-680[CrossRef][Medline].
23. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051[Abstract/Free Full Text].
24. Gruffat, H., N. Duran, M. Buisson, F. Wild, R. Buckland, and A. Sergeant. 1992. Characterization of an R-binding site mediating the R-induced activation of the Epstein-Barr virus BMLF1 promoter. J. Virol. 66:46-52[Abstract/Free Full Text].
25. Gruffat, H., and A. Sergeant. 1994. Characterization of the DNA-binding site repertoire for the Epstein-Barr virus transcription factor R. Nucleic Acids Res. 22:1172-1178[Abstract/Free Full Text].
26. Gupta, S., D. Campbell, B. Derijard, and R. J. Davis. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267:389-393[Abstract/Free Full Text].
27. Hai, T., and T. Curran. 1991. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl. Acad. Sci. USA 88:3720-3724[Abstract/Free Full Text].
28. Hardwick, J. M., P. M. Lieberman, and S. D. Hayward. 1988. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J. Virol. 62:2274-2284[Abstract/Free Full Text].
29. Hardwick, J. M., L. Tse, N. Applegren, J. Nicholas, and M. A. Veliuona. 1992. The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16. J. Virol. 66:5500-5508[Abstract/Free Full Text].
30. Holley-Guthrie, E. A., E. B. Quinlivan, E.-C. Mar, and S. Kenney. 1990. The Epstein-Barr virus (EBV) promoter for early antigen (EA-D) is regulated by the EBV transactivators, BRLF1 and BZLF1, in a cell-specific manner. J. Virol. 64:3753-3759[Abstract/Free Full Text].
31. Johnson, R. A., S.-M. Huong, and E.-S. Huang. 1999. Inhibitory effect of 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidizale (FHPI) on HCMV DNA replication and permissive infection. Antivir. Res. 41:101-111[CrossRef][Medline].
32. Kamei, Y., L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S. C. Lin, R. A. Heyman, D. W. Rose, C. K. Glass, and M. G. Rosenfeld. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414[CrossRef][Medline].
33. Kawasaki, H., J. Song, R. Eckner, H. Ugai, R. Chiu, K. Taira, Y. Shi, N. Jones, and K. K. Yokoyama. 1998. p300 and ATF-2 are components of the DRF complex, which regulates retinoic acid- and E1A-mediated transcription of the c-jun gene in F9 cells. Genes Dev. 12:133-145[Free Full Text].
34. Kenney, S., E. Holley-Guthrie, E. B. Quinlivan, D. Gutsch, Q. Zhang, T. Bender, J.-F. Giot, and A. Sergeant. 1992. The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells. Mol. Cell. Biol. 12:136-146[Abstract/Free Full Text].
35. Kenney, S., E. Holley-Guthrie, E.-C. Mar, and M. Smith. 1989. The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators. J. Virol. 63:3878-3883[Abstract/Free Full Text].
36. Kenney, S., J. Kamine, E. Holley-Guthrie, J.-C. Lin, E.-C. Mar, and J. Pagano. 1989. The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters. J. Virol. 63:1729-1736[Abstract/Free Full Text].
37. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2396. In B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
38. Kieser, A., E. Kilger, O. Gires, M. Ueffing, W. Kolch, and W. Hammerschmidt. 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16:6478-6485[CrossRef][Medline].
39. Kim, S.-J., S. Wagner, F. Liu, M. A. O'Reilly, P. D. Robbins, and M. R. Green. 1992. Retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature 358:331-334[CrossRef][Medline].
40. Kolman, J. L., N. Taylor, L. Gradoville, J. Countryman, and G. Miller. 1996. Comparing transcriptional activation and autostimulation by ZEBRA and ZEBRA/c-Fos chimeras. J. Virol. 70:1493-1504[Abstract].
41. Kwok, R. P. S., J. R. Lundblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger, R. G. Brennan, S. G. E. Roberts, M. R. Green, and R. H. Goodman. 1994. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370:223-226[CrossRef][Medline].
42. Kyriakis, J. M., P. Banerjee, E. Nikolakaki, T. Dai, E. A. Rubie, M. F. Ahmad, J. Avruch, and J. R. Woodgett. 1994. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156-160[CrossRef][Medline].
43. Lawler, S., A. Cuenda, M. Goedert, and P. Cohen. 1997. SKK4, a novel activator of stress-activated protein kinase-1 (SAPK1/JNK). FEBS Lett. 414:153-158[CrossRef][Medline].
44. Le Roux, F., A. Sergeant, and L. Corbo. 1996. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome. J. Gen. Virol. 77:501-509[Abstract/Free Full Text].
45. Li, Q. X., L. S. Young, G. Niedobitek, C. W. Dawson, M. Birkenbach, F. Wang, and A. B. Rickinson. 1992. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 356:347-350[CrossRef][Medline].
46. Lieberman, P. M., J. M. Hardwick, and S. D. Hayward. 1989. Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions. J. Virol. 63:3040-3050[Abstract/Free Full Text].
47. Lillie, J., and M. Green. 1989. Transcriptional activation by the adenovirus E1a protein. Nature 338:39-44[CrossRef][Medline].
48. Liu, F., and M. R. Green. 1990. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 61:1217-1224[CrossRef][Medline].
49. Liu, P., S. Liu, and S. H. Speck. 1998. Identification of a negative cis element within the ZII domain of the Epstein-Barr virus lytic switch BZLF1 gene promoter. J. Virol. 72:8230-8239[Abstract/Free Full Text].
50. Liu, S., P. Liu, A. Borras, T. Chatila, and S. H. Speck. 1997. Cyclosporin A-sensitive induction of the Epstein-Barr virus lytic switch is mediated via a novel pathway involving a MEF2 family member. EMBO J. 16:143-153[CrossRef][Medline].
51. Livingstone, C., G. Patel, and N. Jones. 1995. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J. 14:1785-1797[Medline].
52. Madhani, H. D., and G. R. Fink. 1998. The riddle of MAP kinase signalling. Trends Genet. 14:151-155[CrossRef][Medline].
53. Manet, E., H. Gruffat, M. C. Trescol-Biemont, I. Moreno, P. Chambard, J. F. Giot, and A. Sergeant. 1989. Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators. EMBO J. 8:1819-1826[Medline].
54. Marinissen, M. J., M. Chiariello, M. Pallante, and J. S. Gutkind. 1999. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-jun promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. Mol. Cell. Biol. 19:4289-4301[Abstract/Free Full Text].
55. McLean, T. I., and S. L. Bachenheimer. 1999. Activation of cJUN N-terminal kinase by herpes simplex virus type 1 enhances viral replication. J. Virol. 73:8415-8426[Abstract/Free Full Text].
56. Quinlivan, E., E. Holley-Guthrie, M. Norris, D. Gutsch, S. Bachenheimer, and S. Kenney. 1993. Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1. Nucleic Acids Res. 21:1999-2007.
57. Ragoczy, T., L. Heston, and G. Miller. 1998. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. 1998. J. Virol. 72:7978-7984[Abstract/Free Full Text].
58. Raingeaud, J., S. Gupta, J. Rogers, M. Dickens, J. Han, R. J. Ulevitch, and R. J. Davis. 1995. Pro-inflammatory cytokines and environmental stress cause p38 MAP kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270:7420-7426[Abstract/Free Full Text].
59. Raingeaud, J., A. J. Whitmarsh, T. Barrett, B. Dérijard, and R. J. Davis. 1996. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 16:1247-1255[Abstract].
60. Rehfuss, R. P., K. M. Walton, M. M. Loriaux, and R. H. Goodman. 1991. The c-AMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A. J. Biol. Chem. 266:18431[Abstract/Free Full Text].
61. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, P. M. Howley, et al. (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
62. Rooney, C., N. Taylor, J. Countryman, H. Jenson, J. Kolman, and G. Miller. 1988. Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc. Natl. Acad. Sci. USA 85:9801-9805[Abstract/Free Full Text].
63. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116[Abstract/Free Full Text].
64. Sadowski, I., and M. Ptashne. 1989. A vector for expressing GAL4(1-147) fusions in mammalian cells. Nucleic Acids. Res. 17:7539[Free Full Text].
64a. Sanchez, I., R. T. Hughes, B. J. Mayer, K. Yee, J. R. Woodgett, J. Avruch, J. M. Kyriakis, and L. I. Zon. 1994. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372:794-800[Medline].
65. Shimizu, N., and K. Takada. 1993. Analysis of the BZLF1 promoter of Epstein-Barr virus: identification of an anti-immunoglobulin response sequence. J. Virol. 67:3240-3245[Abstract/Free Full Text].
66. Sinclair, A. J., M. Brimmell, F. Shanahan, and P. J. Farrell. 1991. Pathways of activation of the Epstein-Barr virus productive cycle. J. Virol. 65:2237-2244[Abstract/Free Full Text].
67. Sixby, J. W., J. G. Nedrud, N. Raab-Traub, R. A. Hanes, and J. S. Pagano. 1984. Epstein-Barr virus replication in oropharyngeal epithelial cells. N. Engl. J. Med. 310:1225-1230[Abstract].
68. Takada, K., and Y. Ono. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63:445-449[Abstract/Free Full Text].
69. Takada, K., N. Shimizu, S. Sakuma, and Y. Ono. 1986. trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J. Virol. 57:1016-1022[Abstract/Free Full Text].
70. Takimoto, T., M. Kamide, and R. Umeda. 1984. Establishment of Epstein-Barr virus (EBV)-associated nuclear antigen (EBNA)-positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch. Otorhinolaryngol. 239:87-92[CrossRef][Medline].
71. Tonneguzzo, F., A. C. Hayday, and A. Keating. 1986. Electric field-mediated DNA transfer: transient and stable gene expression in human and mouse lymphoid cells. Mol. Cell. Biol. 6:703-706[Abstract/Free Full Text].
72. Treisman, R. 1996. Regulation of transcription by MAP kinase cascades. Curr. Opin. Cell Biol. 8:205-215[CrossRef][Medline].
73. Uhler, M. D., and G. S. McKnight. 1987. Expression of cDNAs for two isoforms of the catalytic subunit of cAMP-dependent protein kinase. J. Biol. Chem. 262:15202-15207[Abstract/Free Full Text].
74. Urier, G., M. Buisson, P. Chambard, and A. Sergeant. 1989. The Epstein-Barr virus early protein EB1 activates transcription from different responsive elements including AP-1 binding sites. EMBO J. 8:1447-1453[Medline].
75. van Dam, H., D. Wilhelm, I. Herr, A. Steffen, P. Herrlich, and P. Angel. 1995. ATF2 is preferentially activated by stress-activated protein kinases to mediate c-Jun induction in response to genotoxic agents. EMBO J. 14:1798-1811[Medline].
76. Wang, Y.-C., J.-M. Huang, and E. A. Montalvo. 1997. Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1. Virology 227:323-330[CrossRef][Medline].
77. Westphal, E.-M., A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and S. C. Kenney. 1999. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. Cancer Res. 59:1485-1491[Abstract/Free Full Text].
78. Yang, S.-H., A. Galanis, and A. D. Sharrocks. 1999. Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol. Cell. Biol. 19:4028-4038[Abstract/Free Full Text].
79. Zachos, G., B. Clements, and J. Conner. 1999. Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1. J. Biol. Chem. 274:5097-5103[Abstract/Free Full Text].
80. Zalani, S., E. Holley-Guthrie, and S. Kenney. 1996. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc. Natl. Acad. Sci. USA 93:9194-9199[Abstract/Free Full Text].
81. Zerby, D., C.-J. Chen, E. Poon, D. Lee, R. Shiekhattar, and P. M. Lieberman. 1999. The amino-terminal C/H1 domain of CREB binding protein mediates Zta transcriptional activation of latent Epstein-Barr virus. Mol. Cell. Biol. 19:1617-1626[Abstract/Free Full Text].
82. Zur Hausen, H., H. Schulte-Holthauzen, G. Klein, G. Henle, W. Henle, P. Clifford, and L. Santesson. 1970. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228:1956-1958.

Journal of Virology, February 2000, p. 1224-1233, Vol. 74, No. 3
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lee, Y.-H., Chiu, Y.-F., Wang, W.-H., Chang, L.-K., Liu, S.-T. (2008). Activation of the ERK signal transduction pathway by Epstein-Barr virus immediate-early protein Rta. J. Gen. Virol. 89: 2437-2446 [Abstract] [Full Text]  
  • Calderwood, M. A., Holthaus, A. M., Johannsen, E. (2008). The Epstein-Barr Virus LF2 Protein Inhibits Viral Replication. J. Virol. 82: 8509-8519 [Abstract] [Full Text]  
  • Oster, B., Bundgaard, B., Hupp, T. R., Hollsberg, P. (2008). Human herpesvirus 6B induces phosphorylation of p53 in its regulatory domain by a CK2- and p38-independent pathway. J. Gen. Virol. 89: 87-96 [Abstract] [Full Text]  
  • Ho, C.-H., Hsu, C.-F., Fong, P.-F., Tai, S.-K., Hsieh, S.-L., Chen, C.-J. (2007). Epstein-Barr Virus Transcription Activator Rta Upregulates Decoy Receptor 3 Expression by Binding to Its Promoter. J. Virol. 81: 4837-4847 [Abstract] [Full Text]  
  • Chua, H.-H., Lee, H.-H., Chang, S.-S., Lu, C.-C., Yeh, T.-H., Hsu, T.-Y., Cheng, T.-H., Cheng, J.-T., Chen, M.-R., Tsai, C.-H. (2007). Role of the TSG101 Gene in Epstein-Barr Virus Late Gene Transcription. J. Virol. 81: 2459-2471 [Abstract] [Full Text]  
  • Bogoyevitch, M. A., Kobe, B. (2006). Uses for JNK: the Many and Varied Substrates of the c-Jun N-Terminal Kinases. Microbiol. Mol. Biol. Rev. 70: 1061-1095 [Abstract] [Full Text]  
  • Felton-Edkins, Z. A., Kondrashov, A., Karali, D., Fairley, J. A., Dawson, C. W., Arrand, J. R., Young, L. S., White, R. J. (2006). Epstein-Barr Virus Induces Cellular Transcription Factors to Allow Active Expression of EBER Genes by RNA Polymerase III. J. Biol. Chem. 281: 33871-33880 [Abstract] [Full Text]  
  • Heston, L., El-Guindy, A., Countryman, J., Dela Cruz, C., Delecluse, H.-J., Miller, G. (2006). Amino Acids in the Basic Domain of Epstein-Barr Virus ZEBRA Protein Play Distinct Roles in DNA Binding, Activation of Early Lytic Gene Expression, and Promotion of Viral DNA Replication.. J. Virol. 80: 9115-9133 [Abstract] [Full Text]  
  • Feng, W.-h., Kenney, S. C. (2006). Valproic Acid Enhances the Efficacy of Chemotherapy in EBV-Positive Tumors by Increasing Lytic Viral Gene Expression.. Cancer Res. 66: 8762-8769 [Abstract] [Full Text]  
  • Goormachtigh, G., Ouk, T.-S., Mougel, A., Tranchand-Bunel, D., Masy, E., Le Clorennec, C., Feuillard, J., Bornkamm, G. W., Auriault, C., Manet, E., Fafeur, V., Adriaenssens, E., Coll, J. (2006). Autoactivation of the Epstein-Barr Virus Oncogenic Protein LMP1 during Type II Latency through Opposite Roles of the NF-{kappa}B and JNK Signaling Pathways.. J. Virol. 80: 7382-7393 [Abstract] [Full Text]  
  • Chang, Y., Lee, H.-H., Chen, Y.-T., Lu, J., Wu, S.-Y., Chen, C.-W., Takada, K., Tsai, C.-H. (2006). Induction of the early growth response 1 gene by epstein-barr virus lytic transactivator zta.. J. Virol. 80: 7748-7755 [Abstract] [Full Text]  
  • El-Guindy, A. S., Paek, S. Y., Countryman, J., Miller, G. (2006). Identification of Constitutive Phosphorylation Sites on the Epstein-Barr Virus ZEBRA Protein. J. Biol. Chem. 281: 3085-3095 [Abstract] [Full Text]  
  • Huang, J., Liao, G., Chen, H., Wu, F. Y., Hutt-Fletcher, L., Hayward, G. S., Hayward, S. D. (2006). Contribution of C/EBP Proteins to Epstein-Barr Virus Lytic Gene Expression and Replication in Epithelial Cells. J. Virol. 80: 1098-1109 [Abstract] [Full Text]  
  • Chang, L.-K., Chung, J.-Y., Hong, Y.-R., Ichimura, T., Nakao, M., Liu, S.-T. (2005). Activation of Sp1-mediated transcription by Rta of Epstein-Barr virus via an interaction with MCAF1. Nucleic Acids Res 33: 6528-6539 [Abstract] [Full Text]  
  • Hong, G. K., Kumar, P., Wang, L., Damania, B., Gulley, M. L., Delecluse, H.-J., Polverini, P. J., Kenney, S. C. (2005). Epstein-Barr Virus Lytic Infection Is Required for Efficient Production of the Angiogenesis Factor Vascular Endothelial Growth Factor in Lymphoblastoid Cell Lines. J. Virol. 79: 13984-13992 [Abstract] [Full Text]  
  • Adamson, A. L., Wright, N., LaJeunesse, D. R. (2005). Modeling Early Epstein-Barr Virus Infection in Drosophila melanogaster: The BZLF1 Protein. Genetics 171: 1125-1135 [Abstract] [Full Text]  
  • Chen, L.-W., Chang, P.-J., Delecluse, H.-J., Miller, G. (2005). Marked Variation in Response of Consensus Binding Elements for the Rta Protein of Epstein-Barr Virus. J. Virol. 79: 9635-9650 [Abstract] [Full Text]  
  • Hahn, A. M., Huye, L. E., Ning, S., Webster-Cyriaque, J., Pagano, J. S. (2005). Interferon Regulatory Factor 7 Is Negatively Regulated by the Epstein-Barr Virus Immediate-Early Gene, BZLF-1. J. Virol. 79: 10040-10052 [Abstract] [Full Text]  
  • Hargett, D., McLean, T., Bachenheimer, S. L. (2005). Herpes Simplex Virus ICP27 Activation of Stress Kinases JNK and p38. J. Virol. 79: 8348-8360 [Abstract] [Full Text]  
  • Hsu, T.-Y., Chang, Y., Wang, P.-W., Liu, M.-Y., Chen, M.-R., Chen, J.-Y., Tsai, C.-H. (2005). Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal. J. Gen. Virol. 86: 317-322 [Abstract] [Full Text]  
  • Chang, Y., Lee, H.-H., Chang, S.-S., Hsu, T.-Y., Wang, P.-W., Chang, Y.-S., Takada, K., Tsai, C.-H. (2004). Induction of Epstein-Barr Virus Latent Membrane Protein 1 by a Lytic Transactivator Rta. J. Virol. 78: 13028-13036 [Abstract] [Full Text]  
  • Feng, W.-h., Cohen, J. I., Fischer, S., Li, L., Sneller, M., Goldbach-Mansky, R., Raab-Traub, N., Delecluse, H.-J., Kenney, S. C. (2004). Reactivation of Latent Epstein-Barr Virus by Methotrexate: A Potential Contributor to Methotrexate-Associated Lymphomas. JNCI J Natl Cancer Inst 96: 1691-1702 [Abstract] [Full Text]  
  • Li, Y., Mahajan, N. P., Webster-Cyriaque, J., Bhende, P., Hong, G. K., Earp, H. S., Kenney, S. (2004). The C-Mer Gene Is Induced by Epstein-Barr Virus Immediate-Early Protein BRLF1. J. Virol. 78: 11778-11785 [Abstract] [Full Text]  
  • Gao, X., Wang, H., Sairenji, T. (2004). Inhibition of Epstein-Barr Virus (EBV) Reactivation by Short Interfering RNAs Targeting p38 Mitogen-Activated Protein Kinase or c-myc in EBV-Positive Epithelial Cells. J. Virol. 78: 11798-11806 [Abstract] [Full Text]  
  • Hamza, M. S., Reyes, R. A., Izumiya, Y., Wisdom, R., Kung, H.-J., Luciw, P. A. (2004). ORF36 Protein Kinase of Kaposi's Sarcoma Herpesvirus Activates the c-Jun N-terminal Kinase Signaling Pathway. J. Biol. Chem. 279: 38325-38330 [Abstract] [Full Text]  
  • Chang, Y., Chang, S.-S., Lee, H.-H., Doong, S.-L., Takada, K., Tsai, C.-H. (2004). Inhibition of the Epstein-Barr virus lytic cycle by Zta-targeted RNA interference. J. Gen. Virol. 85: 1371-1379 [Abstract] [Full Text]  
  • Hong, G. K., Delecluse, H.-J., Gruffat, H., Morrison, T. E., Feng, W.-H., Sergeant, A., Kenney, S. C. (2004). The BRRF1 Early Gene of Epstein-Barr Virus Encodes a Transcription Factor That Enhances Induction of Lytic Infection by BRLF1. J. Virol. 78: 4983-4992 [Abstract] [Full Text]  
  • Li, Y., Webster-Cyriaque, J., Tomlinson, C. C., Yohe, M., Kenney, S. (2004). Fatty Acid Synthase Expression Is Induced by the Epstein-Barr Virus Immediate-Early Protein BRLF1 and Is Required for Lytic Viral Gene Expression. J. Virol. 78: 4197-4206 [Abstract] [Full Text]  
  • Feng, W.-h., Hong, G., Delecluse, H.-J., Kenney, S. C. (2004). Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas. J. Virol. 78: 1893-1902 [Abstract] [Full Text]  
  • Iwakiri, D., Takada, K. (2004). Phosphatidylinositol 3-Kinase Is a Determinant of Responsiveness to B Cell Antigen Receptor-Mediated Epstein-Barr Virus Activation. J. Immunol. 172: 1561-1566 [Abstract] [Full Text]  
  • Ghosh, S. K., Wood, C., Boise, L. H., Mian, A. M., Deyev, V. V., Feuer, G., Toomey, N. L., Shank, N. C., Cabral, L., Barber, G. N., Harrington, W. J. Jr (2003). Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 101: 2321-2327 [Abstract] [Full Text]  
  • Mauser, A., Saito, S.'i., Appella, E., Anderson, C. W., Seaman, W. T., Kenney, S. (2002). The Epstein-Barr Virus Immediate-Early Protein BZLF1 Regulates p53 Function through Multiple Mechanisms. J. Virol. 76: 12503-12512 [Abstract] [Full Text]  
  • Mauser, A., Holley-Guthrie, E., Zanation, A., Yarborough, W., Kaufmann, W., Klingelhutz, A., Seaman, W. T., Kenney, S. (2002). The Epstein-Barr Virus Immediate-Early Protein BZLF1 Induces Expression of E2F-1 and Other Proteins Involved in Cell Cycle Progression in Primary Keratinocytes and Gastric Carcinoma Cells. J. Virol. 76: 12543-12552 [Abstract] [Full Text]  
  • Feng, W.-h., Westphal, E., Mauser, A., Raab-Traub, N., Gulley, M. L., Busson, P., Kenney, S. C. (2002). Use of Adenovirus Vectors Expressing Epstein-Barr Virus (EBV) Immediate-Early Protein BZLF1 or BRLF1 To Treat EBV-Positive Tumors. J. Virol. 76: 10951-10959 [Abstract] [Full Text]  
  • Keating, S., Prince, S., Jones, M., Rowe, M. (2002). The Lytic Cycle of Epstein-Barr Virus Is Associated with Decreased Expression of Cell Surface Major Histocompatibility Complex Class I and Class II Molecules. J. Virol. 76: 8179-8188 [Abstract] [Full Text]  
  • Chen, J., Stinski, M. F. (2002). Role of Regulatory Elements and the MAPK/ERK or p38 MAPK Pathways for Activation of Human Cytomegalovirus Gene Expression. J. Virol. 76: 4873-4885 [Abstract] [Full Text]  
  • Chang, P.-J., Shedd, D., Gradoville, L., Cho, M.-S., Chen, L.-W., Chang, J., Miller, G. (2002). Open Reading Frame 50 Protein of Kaposi's Sarcoma-Associated Herpesvirus Directly Activates the Viral PAN and K12 Genes by Binding to Related Response Elements. J. Virol. 76: 3168-3178 [Abstract] [Full Text]  
  • Feng, W.-h., Israel, B., Raab-Traub, N., Busson, P., Kenney, S. C. (2002). Chemotherapy Induces Lytic EBV Replication and Confers Ganciclovir Susceptibility to EBV-positive Epithelial Cell Tumors. Cancer Res. 62: 1920-1926 [Abstract] [Full Text]  
  • Darr, C. D., Mauser, A., Kenney, S. (2001). Epstein-Barr Virus Immediate-Early Protein BRLF1 Induces the Lytic Form of Viral Replication through a Mechanism Involving Phosphatidylinositol-3 Kinase Activation. J. Virol. 75: 6135-6142 [Abstract] [Full Text]  
  • Swenson, J. J., Holley-Guthrie, E., Kenney, S. C. (2001). Epstein-Barr Virus Immediate-Early Protein BRLF1 Interacts with CBP, Promoting Enhanced BRLF1 Transactivation. J. Virol. 75: 6228-6234 [Abstract] [Full Text]  
  • Wensing, B., Stuhler, A., Jenkins, P., Hollyoake, M., Karstegl, C. E., Farrell, P. J. (2001). Variant Chromatin Structure of the oriP Region of Epstein-Barr Virus and Regulation of EBER1 Expression by Upstream Sequences and oriP. J. Virol. 75: 6235-6241 [Abstract] [Full Text]  
  • Adamson, A. L., Kenney, S. (2001). Epstein-Barr Virus Immediate-Early Protein BZLF1 Is SUMO-1 Modified and Disrupts Promyelocytic Leukemia Bodies. J. Virol. 75: 2388-2399 [Abstract] [Full Text]  
  • Mogensen, T. H., Paludan, S. R. (2001). Molecular Pathways in Virus-Induced Cytokine Production. Microbiol. Mol. Biol. Rev. 65: 131-150 [Abstract] [Full Text]  
  • Chang, P.-J., Liu, S.-T. (2001). Function of the Intercistronic Region of BRLF1-BZLF1 Bicistronic mRNA in Translating the Zta Protein of Epstein-Barr Virus. J. Virol. 75: 1142-1151 [Abstract] [Full Text]  
  • Chen, J., Stinski, M. F. (2000). Activation of Transcription of the Human Cytomegalovirus Early UL4 Promoter by the Ets Transcription Factor Binding Element. J. Virol. 74: 9845-9857 [Abstract] [Full Text]  
  • Chang, L.-K., Liu, S.-T. (2000). Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res 28: 3918-3925 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adamson, A. L.
Right arrow Articles by Kenney, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adamson, A. L.
Right arrow Articles by Kenney, S.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»